Unknown Analyst
Good afternoon, ladies and gentlemen. Welcome to the 2026 JPMorgan Healthcare Conference. My name is Varun, and it is my absolute pleasure to introduce on stage AbCellera Biologics, joined by the CEO, Carl Hansen, who will talk about the company and their growth for the year. So please give a huge round of applause for Carl Hansen.
Carl L. Hansen
CEO, President & Chairperson
All right. Thank you very much, and thank you to the organizers of JPMorgan for the opportunity to speak. So today, in my prepared remarks, I’ll try to keep pretty brief. For those that don’t know us well, I’ll give a little bit of history in the company. I’ll then give you an update on our portfolio and in particular, our lead asset, ABCL635 and then maybe lay out for you why we’re excited about the future of the company, why we think the next 6 months to 18 months is very interesting in terms of the development of our portfolio and our transition from what has been historically a technology and platform-based story to a clinical company with multiple assets and some pretty interesting readouts that are coming soon.
So for those that don’t know us, AbCellera is a biotechnology company. The center of mass is located in Vancouver, Canada, where we have roughly 500 employees. We also have facilities in Sydney, Australia with about 50 employees and a clinical development group in Montreal, Canada. The company was founded in 2012 from my academic lab at the University of British Columbia, where I was a professor. And so we have now been at this. We’re coming into our 14th year. Through the
